Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) have received an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $36.70.
A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $48.00 price objective on shares of Alkermes in a report on Thursday, October 10th. HC Wainwright reissued a “neutral” rating and issued a $37.00 price target on shares of Alkermes in a research note on Monday, October 14th. StockNews.com raised shares of Alkermes from a “hold” rating to a “buy” rating in a research report on Sunday, July 28th. Robert W. Baird upped their price objective on Alkermes from $37.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Finally, JPMorgan Chase & Co. raised their target price on Alkermes from $31.00 to $32.00 and gave the stock a “neutral” rating in a research note on Thursday, July 25th.
Get Our Latest Analysis on Alkermes
Institutional Trading of Alkermes
Alkermes Price Performance
ALKS stock opened at $26.85 on Tuesday. Alkermes has a 1 year low of $22.01 and a 1 year high of $32.88. The firm has a market capitalization of $4.54 billion, a PE ratio of 10.61, a price-to-earnings-growth ratio of 0.56 and a beta of 0.46. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.99 and a quick ratio of 2.61. The business has a 50 day simple moving average of $27.85 and a 200-day simple moving average of $25.87.
Alkermes (NASDAQ:ALKS – Get Free Report) last issued its earnings results on Wednesday, July 24th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. The business had revenue of $399.13 million during the quarter, compared to the consensus estimate of $393.30 million. Alkermes had a return on equity of 23.20% and a net margin of 19.15%. The company’s revenue for the quarter was down 35.4% on a year-over-year basis. During the same period last year, the company earned $0.38 EPS. Equities research analysts anticipate that Alkermes will post 2.36 earnings per share for the current fiscal year.
About Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Read More
- Five stocks we like better than Alkermes
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Buy P&G Now, Before It Sets A New All-Time High
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- About the Markup Calculator
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.